NCT03777761View on ClinicalTrials.gov

Effects of Tucatinib on Cardiac Repolarization in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

December 6, 2018

Primary Completion Date

March 11, 2019

Study Completion Date

March 11, 2019

Conditions
Healthy
Interventions
DRUG

tucatinib

300mg oral dose

DRUG

placebo

Matching placebo for tucatinib

DRUG

moxifloxacin

400mg single oral dose

Trial Locations (1)

75247

Covance Clinical Research Unit - Dallas, Dallas

All Listed Sponsors
lead

Seagen Inc.

INDUSTRY

NCT03777761 - Effects of Tucatinib on Cardiac Repolarization in Healthy Participants | Biotech Hunter | Biotech Hunter